Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
| ▸ | PREP | P48147 | 1/20 | 0.37 |
| ▸ | TMEM97 | Q5BJF2 | 8/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | CASP3 | P42574 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6496189 | 0.99 | HRH3 (0.39) | HRH3PREPTMEM97SIGMAR1L3MBTL1 | |
| SCHEMBL6487261 | 0.93 | TMEM97 (0.42) | HRH3TMEM97SIGMAR1MEN1KMT2A | |
| SCHEMBL6497464 | 0.92 | DRD3 (0.41) | PREPTMEM97SIGMAR1ALDH1A1CYP2D6 | |
| SCHEMBL6486752 | 0.89 | TMEM97 (0.36) | TMEM97SIGMAR1ALDH1A1CASP3 | |
| SCHEMBL6487338 | 0.89 | TMEM97 (0.47) | HRH3TMEM97SIGMAR1SMN1; SMN2MEN1 | |
| SCHEMBL6499661 | 0.85 | TMEM97 (0.43) | TMEM97SIGMAR1 | |
| SCHEMBL6499143 | 0.85 | CYP19A1 (0.37) | TMEM97SIGMAR1CYP2D6 | |
| SCHEMBL6487418 | 0.85 | ALDH1A1 (0.36) | TMEM97SIGMAR1ALDH1A1CASP3 | |
| SCHEMBL6485050 | 0.84 | POLB (0.39) | PREPL3MBTL1SMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL6489882 | 0.84 | TMEM97 (0.43) | HRH3TMEM97SIGMAR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6869958-B2 | Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-03-22 | — | — | US | disclosed |
| US-20040038960-A1 | Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors | LI JIE JACK (US) | 2004-02-26 | — | — | US | disclosed |
| WO-2004014909-A1 | FUSED TETRAHYDROPYRIDINE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038960-A1 | Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors | MMP9, MMP3, MMP13 | HRH3 1410/4885PREP 46/4885TMEM97 3966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.